PAR-1 antagonists: Current state of evidence

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 1, 2013, Pages 1-9

  Chatterjee, Saurav ^a   Sharma, Abhishek ^a   Mukherjee, Debabrata ^b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Coronary artery disease; Meta analysis; Percutaneous coronary intervention; Vorapaxar

Indexed keywords

ATOPAXAR; PLACEBO; VORAPAXAR;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW;

CORONARY ARTERY DISEASE; HEMORRHAGE; HUMANS; IMINES; LACTONES; PLATELET AGGREGATION INHIBITORS; PUBMED; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, PAR-1;

EID: 84871794080     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0752-4     Document Type: Article

References (35)

1. Yusuf S, Zhao F, Mehta SR et al (2001) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
2. Andersen H, Greenberg DL, Fujikawa K et al (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96:11189-11193
3. Dorsam RT, Tuluc M, Kunapuli SP (2004) Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost 2:804-812
4. Lundblad RL, White GC II (2005) The interaction of thrombin with blood platelets. Platelets 16:373-385
5. Kim S, Foster C, Lecchi A et al (2002) Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99:3629-3636
6. Merlini PA, Bauer KA, Oltrona L et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61-68
7. Connolly SJ, Ezekowitz MD, Yusuf S et al; RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
8. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397-402
9. Kosoglou T, Reyderman L, Tiessen RG et al (2012) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 68:249-258
10. Becker RC, Moliterno DJ, Jennings LK et al; TRA-PCI Investigators (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919-928
11. Goto S, Ogawa H, Takeuchi M et al; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 31:2601-2613
12. Goto S, Yamaguchi T, Ikeda Y et al (2010) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156-164
13. O'Donoghue ML, Bhatt DL, Wiviott SD et al; LANCELOT-ACS Investigators (2011) Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 123:1843-1853
14. Tricoci P, Huang Z, Held C et al; TRACER Investigators (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20-33
15. http://www.clinicaltrials.gov/ct2/show/NCT00526474?term= TRA+2%E2%81%B0P+TIMI-50&rank=1. Accessed 31 Mar 2012
16. Morrow DA, Scirica BM, Fox KA et al; TRA 2(o)P-TIMI 50 Investigators (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 158:335.e3-341.e3
17. Morrow DA, Braunwald E, Bonaca MP et al; the TRA 2P-TIMI 50 Steering Committee and Investigators (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404-1413
18. Wiviott SD, Flather MD, O'Donoghue ML et al; LANCELOT-CAD Investigators (2011) Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 123:1854-1863
19. Angiolillo DJ, Fernández-Ortiz A, Bernardo E et al (2004) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25:1903-1910
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115:101-108
21. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505-1516
23. Holmes MV, Perel P, Shah T et al (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306:2704-2714
24. Valgimigli M, Campo G, de Cesare N et al; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators (2009) Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119:3215-3222
25. Campo G, Fileti L, Valgimigli M et al (2010) Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. J Blood Med 1:61-69
26. Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213-223
27. Jernberg T, Payne CD, Winters KJ et al (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27:1166-1173
28. Wiviott SD, Braunwald E, McCabe CH et al; TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 357:2001-2015
29. Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456-1462
30. Wallentin L, Becker RC, Budaj A et al; PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 361:1045-1057
31. Ibbotson T, McGavin JK, Goa KL (2003) Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 63:1121-1163
32. Théroux P, Alexander J Jr, Pharand C et al (2000) Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 102:2466-2472
33. Alexander JH, Harrington RA (1998) Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs 56:965-976
34. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100
35. Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester